JP2004500110A - 自己反応性ｔ細胞による組織破壊をブロックする方法 - Google Patents

自己反応性ｔ細胞による組織破壊をブロックする方法 Download PDF

Info

Publication number
JP2004500110A
JP2004500110A JP2001570286A JP2001570286A JP2004500110A JP 2004500110 A JP2004500110 A JP 2004500110A JP 2001570286 A JP2001570286 A JP 2001570286A JP 2001570286 A JP2001570286 A JP 2001570286A JP 2004500110 A JP2004500110 A JP 2004500110A
Authority
JP
Japan
Prior art keywords
hsa
polypeptide
cells
human
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001570286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004500110A5 (enExample
Inventor
リウ，　ヤン
チェン，　パン
バイ，　シュエ−フェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Publication of JP2004500110A publication Critical patent/JP2004500110A/ja
Publication of JP2004500110A5 publication Critical patent/JP2004500110A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
JP2001570286A 2000-03-29 2001-03-29 自己反応性ｔ細胞による組織破壊をブロックする方法 Pending JP2004500110A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19281400P 2000-03-29 2000-03-29
PCT/US2001/040390 WO2001072325A1 (en) 2000-03-29 2001-03-29 Methods of blocking tissue destruction by autoreactive t cells

Publications (2)

Publication Number Publication Date
JP2004500110A true JP2004500110A (ja) 2004-01-08
JP2004500110A5 JP2004500110A5 (enExample) 2008-05-15

Family

ID=22711138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001570286A Pending JP2004500110A (ja) 2000-03-29 2001-03-29 自己反応性ｔ細胞による組織破壊をブロックする方法

Country Status (8)

Country Link
EP (1) EP1267909B1 (enExample)
JP (1) JP2004500110A (enExample)
AT (1) ATE475428T1 (enExample)
AU (2) AU2001259792B2 (enExample)
CA (1) CA2404340C (enExample)
DE (1) DE60142684D1 (enExample)
DK (1) DK1267909T3 (enExample)
WO (1) WO2001072325A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527168A (ja) * 2010-04-28 2013-06-27 オンコイミューン， インコーポレイテッド 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
JP2018501302A (ja) * 2014-11-06 2018-01-18 チルドレンズ リサーチ インスティテュート、チルドレンズ ナショナル メディカル センター 癌及び自己免疫疾患のための免疫療法剤
JP2018515605A (ja) * 2015-05-07 2018-06-14 オンコイミューン， インコーポレイテッド 低密度リポタンパク質コレステロールレベルを低下させるためのｃｄ２４の使用
JP2020510020A (ja) * 2017-03-07 2020-04-02 オンコイミューン， インコーポレイテッド 全身性エリテマトーデスを治療するために可溶性ｃｄ２４を使用する方法
JP2020519627A (ja) * 2017-05-15 2020-07-02 オンコイミューン， インコーポレイテッド 神経保護および再ミエリン化のための可溶性ｃｄ２４の使用方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030106084A1 (en) 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
BR112015000310A2 (pt) * 2012-07-13 2017-06-27 Univ Pennsylvania conjugado droga-molécula, e, método para inibir o esgotamento do tecido saudável durante a terapia com células t car
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
CN107109420A (zh) 2014-07-21 2017-08-29 诺华股份有限公司 使用cll－1嵌合抗原受体的癌症治疗
WO2017025963A1 (en) * 2015-08-10 2017-02-16 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods and pharmaceutical compositions for improving wound healing using cd24
WO2017136492A1 (en) * 2016-02-02 2017-08-10 Oncoimmune, Inc. Use of cd24 proteins for treating leptin-deficient conditions
AU2019284911A1 (en) 2018-06-13 2020-12-17 Novartis Ag BCMA chimeric antigen receptors and uses thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
JPN6010066471, Ｃｌｉｎ． Ｅｘｐ． Ｉｍｍｕｎｏｌ．, 1997, ｖｏｌ． １０８, ５２−５７ *
JPN6010066474, Ｅｕｒ． Ｊ． Ｉｍｍｕｎｏｌ．, 1997, ｖｏｌ． ２７, ２５２４−２５２８ *
JPN6010066476, Ｊ． Ｉｍｍｕｎｏｌ．, 1991, ｖｏｌ． １４７, １４１２−１４１６ *
JPN6010066478, Ｉｎｔ． Ｉｍｍｕｎｏｌ．, 1995, ｖｏｌ． ７, １５５７−１５６５ *
JPN6010066480, Ｂｉｏｃｈｅｍ． Ｂｉｏｐｈｙｓ． Ｒｅｓ． Ｃｏｍｍｕｎ．, 1996, ｖｏｌ． ２２２, ７４２−７４７ *
JPN6010066482, Ｅｕｒ． Ｊ． Ｉｍｍｕｎｏｌ．, 1991, ｖｏｌ． ２１, １０３９−１０４６ *
JPN6010066484, Ｐｒｏｃ． Ｎａｔｌ． Ａｃａｄ． Ｓｃｉ． ＵＳＡ, 1992, ｖｏｌ． ８９, ６８７１−６８７５ *
JPN6010066485, Ｊ． Ｅｘｐ． Ｍｅｄ．, 1994, ｖｏｌ． １７９, １３９１−１３９５ *
JPN6010066488, Ｅｘｐ． Ｄｅｒｍａｔｏｌ．, 1995, ｖｏｌ． ４, ２９１−２９５ *
JPN6010066491, Ｊ． Ｅｘｐ． Ｍｅｄ．, 1997, ｖｏｌ． １７９, １７７−１８４ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527168A (ja) * 2010-04-28 2013-06-27 オンコイミューン， インコーポレイテッド 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
JP2015187162A (ja) * 2010-04-28 2015-10-29 オンコイミューン， インコーポレイテッド 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
JP2017057216A (ja) * 2010-04-28 2017-03-23 オンコイミューン， インコーポレイテッド 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
JP2018127493A (ja) * 2010-04-28 2018-08-16 オンコイミューン， インコーポレイテッド 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
JP2019151655A (ja) * 2010-04-28 2019-09-12 オンコイミューン， インコーポレイテッド 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
JP2018501302A (ja) * 2014-11-06 2018-01-18 チルドレンズ リサーチ インスティテュート、チルドレンズ ナショナル メディカル センター 癌及び自己免疫疾患のための免疫療法剤
JP2018515605A (ja) * 2015-05-07 2018-06-14 オンコイミューン， インコーポレイテッド 低密度リポタンパク質コレステロールレベルを低下させるためのｃｄ２４の使用
JP2020510020A (ja) * 2017-03-07 2020-04-02 オンコイミューン， インコーポレイテッド 全身性エリテマトーデスを治療するために可溶性ｃｄ２４を使用する方法
JP2020519627A (ja) * 2017-05-15 2020-07-02 オンコイミューン， インコーポレイテッド 神経保護および再ミエリン化のための可溶性ｃｄ２４の使用方法

Also Published As

Publication number Publication date
WO2001072325A1 (en) 2001-10-04
EP1267909B1 (en) 2010-07-28
ATE475428T1 (de) 2010-08-15
CA2404340A1 (en) 2001-10-04
EP1267909A4 (en) 2006-05-03
DK1267909T3 (da) 2010-11-08
AU5979201A (en) 2001-10-08
EP1267909A1 (en) 2003-01-02
WO2001072325A9 (en) 2003-02-20
CA2404340C (en) 2012-10-16
AU2001259792B2 (en) 2005-12-22
DE60142684D1 (de) 2010-09-09

Similar Documents

Publication Publication Date Title
JP5379107B2 (ja) 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ）
US20130296249A1 (en) Methods of blocking tissue destruction by autoreactive t cells
JP4350301B2 (ja) 可溶性ｍｈｃ複合体とその利用法
Bai et al. The heat-stable antigen determines pathogenicity of self-reactive T cells in experimental autoimmune encephalomyelitis
US20080166336A1 (en) CD137 agonists to treat patients with IgE-mediated conditions
JP2002514895A (ja) ブタ細胞相互作用タンパク質
JPH09509826A (ja) 活性化ｃｄ４▲上＋▼ｔ細胞の表層上のレセプターに対するリガンド（ａｃｔ−４−ｌ）
JP2009240311A (ja) 活性化されたｔ細胞の表面上のレセプタ：ａｃｔ−４
BG65242B1 (bg) Свързващи протеини и рецептори на остеопротегерин
JP2001508430A (ja) 免疫抑制因子のエンドサイトーシスによる提示のための化合物、組成物及び方法
US8980244B2 (en) Method of treating type 1 diabetes by administering NKp46 polypeptide
AU2001259792B2 (en) Methods of blocking tissue destruction by autoreactive T cells
JP2004290196A (ja) Ｆａｓ抗原を結合するリガンド
AU2001259792A1 (en) Methods of blocking tissue destruction by autoreactive T cells
JPH11511650A (ja) 改変されたミエリンタンパク質分子
JP2004500110A5 (enExample)
US5753502A (en) Neuron-specific ICAM-4 promoter
US20030095966A1 (en) Method of blocking tissue destruction by autoreactive T cells
US5702917A (en) Polynucleotides encoding human ICAM-4
US5773293A (en) Anti-ICAM-4 antibodies and hybridomas
US6841152B1 (en) Methods for protecting against autoimmune diabetes
US20050214290A1 (en) Methods of blocking tissue destruction by autoreactive T cells
JP2021523892A (ja) Ｏｃａ−ｂペプチドコンジュゲート及び処置方法
US5852170A (en) ICAM-4 materials and methods
EP0956508A1 (en) Icam-4 and diagnostic uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110411